Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1223 - Efficacy of T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with pertuzumab (103P)


18 Nov 2017


Poster lunch


Cytotoxic Therapy;  Breast Cancer


Koshi Matsui


Annals of Oncology (2017) 28 (suppl_10): x26-x34. 10.1093/annonc/mdx654


K. Matsui1, A. Yoshikawa2, K. Oyama3, Z. Nozaki4, Y. Tanada4, M. Earashi5, K. Kiyohara6, T. Nagata7, W. Fukushima8, T. Shimizu9, K. Maeda10

Author affiliations

  • 1 Surgery, Toyama Prefectural Central Hospital, 930-8550 - Toyama/JP
  • 2 Department Of Surgery, Toyama City Hospital, 9398511 - Toyama/JP
  • 3 Department Of Surgery, Kouseiren Takaoka Hospital, 9338555 - Takaoka/JP
  • 4 Department Of Surgery, Toyama Red Cross Hospital, 9300859 - Toyama/JP
  • 5 Surgery, Yatsuo general hospital, 9392376 - Toyama/JP
  • 6 Department Of Surgery, Tonami General Hospital, 9391395 - Tonami/JP
  • 7 Department Of Surgery, Toyama University Hospital, 9300194 - Toyama/JP
  • 8 Derartment Of Surgery, Takaoka City Hospital, 933-8550 - Takaoka/JP
  • 9 Department Of Surgery, Saiseikai Toyama Hospital, 9318533 - Toyama/JP
  • 10 Depertment Of Surgery, Toyama Prefectural Central Hospital, 938550 - Toyama city/JP


Abstract 1223


The standard therapy for primary treatment of HER2-positive metastatic breast cancer (MBC) is combination therapy of pertuzumab (PER), trastuzumab (HER) and docetaxel (DTX). Although the effectiveness of trastuzumab emtansine (T-DM1) after HER treatment has been reported, there are few reports on the effectiveness of T-DM1 for patients treated with PER. We retrospectively investigated the effectiveness of T-DM1 on HER2-positive MBC previously treated with PER.


Between October 2013 and June 2017, 79 patients with HER2-positive MBC were treated with PER. 44 patients were investigated the subsequent treatment. 34 patients received T-DM1, and 10 patients received treatment other than T-DM1 after PER treatment.


Median treatment line was 3.0 (1-9) vs 4.0 (1-9) in the T-DM1 treatment and other than T-DM1 treatment, respectively. The response rate was CR 0% vs 0%, PR 36.0% vs 25%, SD 32.0% vs 62.5%, PD 32.0% vs 12.5%, respectively. The objective response rate was 36.0% vs 20.0%. The clinical benefit rate was 48.0% vs 50.0%. Median time to treatment failure was 6.6 months vs 2.9 months, respectively. There was a significant difference in median overall survival; median not reached vs 19.6 months (p = 0.04).


OS was significantly better with administration of T-DM1 after PER treatment. Based on the results of this study, it was confirmed that efficacy of T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with PER.

Clinical trial identification

Legal entity responsible for the study

Koshi Matsui




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.